Heart Failure – Landscape & Forecast – Disease Landscape & Forecast (G7)

Heart failure (HF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. Acute heart failure (AHF) and chronic heart failure (CHF) have distinct treatment pathways, and both are covered in this report. The use of sacubitril / valsartan (Entresto) and SGLT-2 inhibitors is expanding for CHF. Despite the availability of these treatments, substantial unmet needs remain in the treatment of CHF. The CHF therapy market will expand over the 2024-2034 forecast period, fueled by the continued uptake of branded therapies, including the launch of new drugs addressing unmet needs and the increase in the prevalence of heart failure over the forecast period. We forecast several therapies to launch for heart failure with preserved ejection fraction (HFpEF) during the forecast period, including Bayer’s finerenone, Eli Lilly’s tirzepatide, Novo Nordisk’s semaglutide 2.4 mg and ziltivekimab, Boehringer Ingelheim’s vicadrostat, AstraZeneca’s balcinrenone / dapagliflozin FDC, and Amgen’s maridebart cafraglutide (MariTide).

QUESTIONS ANSWERED

• What is the incidence of AHF events and the prevalence of CHF cases in the major pharmaceutical markets under study?
• What are the drivers and constraints in the heart failure therapy market, and how will the market evolve through 2034?
• What are the greatest unmet needs in the treatment of heart failure? Which drugs in development will fulfill these unmet needs?
• How will the treatment of HFpEF evolve following the launch of novel therapies for this population?
• Which emerging therapies generate the most enthusiasm among thought leaders, and what is the expected level of market penetration of these agents?

CONTENT HIGHLIGHTS

• Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
• Primary research: Country-specific interviews with thought-leading cardiologists. Survey data collected for this and other Clarivate research.
• Epidemiology: Diagnosed events of AHF by country and diagnosed prevalence of CHF by country, segmented by ejection fraction.
• Drug treatments: Coverage of key current and emerging therapies.
• Market forecast features: 10-year, annualized, drug-level sales and patient share of key heart failure therapies through 2034, segmented by brands / generics and epidemiological subpopulations.

PRODUCT DESCRIPTION

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.